Literature DB >> 9322877

Pharmacokinetics of the taxanes.

C M Kearns1.   

Abstract

The pharmacokinetics of the taxanes paclitaxel and docetaxel have been studied extensively in humans. Paclitaxel has distinctly nonlinear pharmacokinetics, with saturable distribution and elimination features. Docetaxel pharmacokinetics are well described by linear processes, although some investigators detected subtle nonlinear characteristics. Clinically, nonlinear pharmacokinetics produce a disproportional relationship between dose and drug exposure. This affects dose adjustments and calculation and use of dose intensity to compare chemotherapy regimens. Although the underlying mechanism of nonlinearity in paclitaxel disposition is not well understood, both metabolic and distributive processes may be involved.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322877

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 3.  Docetaxel: a review of its use in metastatic breast cancer.

Authors:  Katherine A Lyseng-Williamson; Caroline Fenton
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Docetaxel: an update of its use in advanced breast cancer.

Authors:  D P Figgitt; L R Wiseman
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).

Authors:  A Furtlehner; J Schueller; I Jarisch; E Ostermann; M Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

6.  Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850).

Authors:  Julie A Straub; Donald E Chickering; Jonathan C Lovely; Huimin Zhang; Bhavdeep Shah; William R Waud; Howard Bernstein
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

7.  Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel.

Authors:  Max Tsai; Ze Lu; Jie Wang; Teng-Kuang Yeh; M Guillaume Wientjes; Jessie L-S Au
Journal:  Pharm Res       Date:  2007-04-20       Impact factor: 4.200

8.  Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.

Authors:  Charity D Scripture; William D Figg; Alex Sparreboom
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

9.  Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.

Authors:  A N Hughes; M J Griffin; D R Newell; A H Calvert; A Johnston; B Kerr; C Lee; B Liang; A V Boddy
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.